Skip to main content
Public offering could pull in $281.7M for Exact Sciences

An underwritten public offering of 7 million shares of common stock has been priced by Exact Sciences in hopes of obtaining gross proceeds of approximately $281.7 million. Proceeds from the offering, which includes an overallotment option for the underwriters to buy almost 1.1 million additional shares, will be used to support commercial expansion for the Cologuard colon cancer test, as well as for product development, working capital and general corporate functions.

Full Story: